AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.

Stuart Elliott in America. (Opinion).(Bayer and its anti-anthrax medication, Cipro)(Brief Article)

Campaign

| November 02, 2001 | Elliott, Stuart | COPYRIGHT 2003 Haymarket Business Publications Ltd. (Hide copyright information)Copyright

It's an advertiser's dream: your brand, hitherto unknown to 99.9 per cent of the general population, suddenly becomes a household word, so much in demand that consumers clamour for it like children for ice-cream in summertime. The anchorman of one of the three national network TV nightly newscasts holds up a package to the camera and praises it by replacing "God" with your brand name in the American motto: "In God we trust."

Almost immediately thereafter, though, the era of good feelings comes to an abrupt end. Your brand is derided, even castigated, as your company is branded an unpatriotic profiteer. Congress seeks to break your patent on the product, of all things, …

Related articles from newspapers, magazines, journals, and more
Ranbaxy to gain royalty from Bayer for Cipro.
News wire article from: Asia Africa Intelligence Wire December 17, 2002 700+ words
Bayer faces competition for Cipro on US market (Neuer Konkurrent fur Bayer).
News wire article from: Europe Intelligence Wire June 11, 2004 700+ words
CHIMIE HEBDO: Bayer's Cipro at centre of fears about anthrax infection.
News wire article from: Chemical Business Newsbase November 1, 2001 700+ words
EUROPEAN CHEMICAL NEWS: Bayer: Cipro will not balance Baycol losses.
News wire article from: Chemical Business Newsbase November 6, 2001 700+ words
Bayer's Cipro faces new generic competition.
News wire article from: Asia Africa Intelligence Wire June 21, 2004 700+ words
©2013 Gale, a part of Cengage Learning. All rights reserved. Contact us | Privacy policy | Terms and conditions

The AccessMyLibrary advertising network includes: womensforum.com GlamFamily